KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (Diluted Average): 2013-2025

Historic Shares Outstanding (Diluted Average) for Xenon Pharmaceuticals (XENE) over the last 5 years, with Sep 2025 value amounting to $79.2 million.

  • Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1.70% to $79.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.2 million, marking a year-over-year increase of 1.70%. This contributed to the annual value of $77.9 million for FY2024, which is 16.45% up from last year.
  • Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $79.2 million in Q3 2025, which was up 0.37% from $79.0 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $79.2 million in Q3 2025 and a low of $42.1 million during Q2 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $73.9 million, with a median of $77.7 million in 2024.
  • Data for Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 54.86% (in 2022) over the last 5 years.
  • Over the past 5 years, Xenon Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $43.6 million in 2021, then spiked by 38.77% to $60.5 million in 2022, then grew by 10.48% to $66.9 million in 2023, then rose by 16.45% to $77.9 million in 2024, then climbed by 1.70% to $79.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $79.2 million for Q3 2025, versus $79.0 million for Q2 2025 and $78.7 million for Q1 2025.